HyQvias label expansion is based on data from the randomized, placebo-controlled ADVANCE-CIDP 1 trial and single-arm open-label extension ADVANCE-CIDP 3 trial, each of which revealed a favorable safety profile for the treatment
Without refrigeration, the peptide begins to degrade, and within a few days, the molecules will break down completely
But with the right habits, you can maintain your results long-term
Abstract The depletion of ovarian reserve is a major factor contributing to the decline in female fertility
In this phase 2 study, 48 patients with obesity or who were overweight and also had alcohol use disorder were randomly assigned either a placebo or a low dose of semaglutide, with researchers testing how much the drug changed drinking habits after about two months
Clinical Trial Registration Number: NCT04270578 Supported by: BMBF 01GI0925 Disclosure: D